1. Lamarcus Aldridge
2. Interesting Llama Facts
3. Dalai Lama
4. Lamar Odom Net Worth
5. Lamar Jackson Highlights Mix
6. What Do Llamas Do

Lama (n.) 'Buddhist priest of Mongolia or Tibet,' 1650s, according to OED from Tibetan blama 'chief, high priest,' with silent b.Related: Lamaism; lamarchy. Lamasery 'Buddhist monastery' (1849) is from French lamaserie, perhaps a word invented in French, as if from Persian sarai 'an inn' (see caravanserai). Definition of lama: a Lamaist monk Examples of lama in a Sentence Recent Examples on the Web There were many such lineages of lamas in Tibet, and the Dalai Lama was just one of them until 1642. Lama (Tibetan: བླ་མ་, Wylie: bla-ma; 'chief' ) is a title for a teacher of the Dharma in Tibetan Buddhism. The name is similar to the Sanskrit term guru, meaning 'heavy one', endowed with qualities the student will eventually embody. The Tibetan word 'Lama' means 'highest principle', and less literally 'highest mother' or 'highest. Aclidinium: Aclidinium is a twice daily LAMA. A Cochrane systematic review of 12 RCTs (9,547 participants) showed that, compared to placebo, aclidinium resulted in marginal improvements in quality of life and FEV 1, and reduced the number of patients with exacerbations requiring hospitalisation (NNT 77, 95% CI 51 to 233) ( Ni 2014 ) evidence. This is a functionality within SAP LaMa that allows customers to easily extend, customize, modify, or even replace existing workflows within the solution. You can also easily integrate other tools with LaMa using Automation Studio. The table below lists some of the customization types that are supported with automation studio.

Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

lama

Tibetan or Mongolian Buddhist monk

la·ma

(lä′mə)n.

lama

(

Lamarcus Aldridge

ˈlɑːmə)

la•ma

(ˈlɑ mə)
n., pl. -mas.

Noun	1.	lama - a Tibetan or Mongolian priest of Lamaism Dalai Lama, Grand Lama - chief lama and once ruler of Tibet Panchen Lama - the lama next in rank to the Dalai Lama non-Christian priest, priest - a person who performs religious duties and ceremonies in a non-Christian religion
2.	Lama - llamas mammal genus - a genus of mammals Camelidae, family Camelidae - camels and llamas and vicunas domestic llama, Lama peruana - used in the Andes as a beast of burden and source of wool; considered a domesticated variety of the guanaco Lama pacos, alpaca - domesticated llama with long silky fleece; believed to be a domesticated variety of the guanaco

lama

lama

[ˈlɑːmə]N → lamam

lama

Interesting Llama Facts

Dalai Lama

Want to thank TFD for its existence? Tell a friend about us, add a link to this page, or visit the webmaster's page for free fun content.
Link to this page:

O1.2 Long-acting bronchodilators

Long-acting bronchodilators produce significant improvements in lung function, symptoms and quality of life (Braido 2013), as well as decreasing exacerbations. These benefits come at a cost of increased adverse effects, which are generally of mild to moderate severity.

O1.2.1 Long-acting muscarinic antagonists (LAMA)

Long-acting muscarinic antagonists (LAMAs) result in bronchodilation with a duration of action of 12 to 24 hours, depending on the agent. A number of LAMAs are available in Australia, which are delivered via a range of devices:

• aclidinium (Genuair)
• glycopyrronium (Breezhaler)
• tiotropium (HandiHaler, Respimat)
• umeclidinium (Ellipta)

Lamar Odom Net Worth

Aclidinium: Aclidinium is a twice daily LAMA. A Cochrane systematic review of 12 RCTs (9,547 participants) showed that, compared to placebo, aclidinium resulted in marginal improvements in quality of life and FEV₁, and reduced the number of patients with exacerbations requiring hospitalisation (NNT 77, 95% CI 51 to 233) (Ni 2014) [evidence level I]. Aclidinium has also been shown to reduce the rate of moderate to severe exacerbations (OR 0.80) (Wedzicha 2016a) [evidence level I].

Glycopyrronium: Once daily glycopyrronium demonstrated significant improvement in spirometry and a reduction in the rate of moderate to severe exacerbations, but no difference in quality of life, compared with placebo (D’Urzo 2011, Kerwin 2012) [evidence level II]. In an RCT comparing glycopyrronium to tiotropium, there was no difference in FEV₁, dyspnoea, quality of life, exacerbation rate or adverse effects (Chapman 2014) [evidence level II].

Lamar Jackson Highlights Mix

Tiotropium: Once daily tiotropium resulted in improved quality of life, and reduced exacerbation rates (OR 0.78, 95% CI 0.70 to 0.87; NNT 16, 95% CI 10 to 36) compared to placebo, in a Cochrane systematic review of 22 studies (23,309 participants) (Karner 2014) [evidence level I]. Tiotropium improved FEV₁ (mean difference 119 mL, 95% CI 113 to 125), and there was no overall difference in mortality.

What Do Llamas Do

Compared to ipratropium, tiotropium had beneficial effects for quality of life, dyspnoea and exacerbation rates (Yohannes 2011b) [evidence level I]. Compared to LABAs, tiotropium reduced exacerbation rates (Vogelmeier 2011, Decramer 2013) [evidence level II], whereas effects were heterogeneous for quality of life, compared to various LABAs (Chong 2012, Decramer 2013) [evidence level II].

Umeclidinium: Once-daily umeclidinium significantly improved lung function, dyspnoea and quality of life, compared with placebo (Trivedi 2014) [evidence level II]. Umeclidinium resulted in a greater improvement in FEV₁ than tiotropium_, but there were no significant differences between umeclidinium and tiotropium for dyspnoea, SGRQ or CAT scores (Feldman 2016) [evidence level II].

Adverse effects of LAMAs include dry mouth, constipation and urinary retention (Halpin 2015). A safety study showed similar rates of death and exacerbations with tiotropium HandiHaler and tiotropium Respimat (Wise 2013) [evidence level II].

Network meta-analyses of LAMAs: A network meta-analysis of LAMAs versus placebo showed that there were no statistically significant differences among LAMAs in preventing moderate-to-severe COPD exacerbations (Oba 2015) [evidence level I]. Tiotropium HandiHaler was the only LAMA formulation which reduced severe exacerbations (HR 0.73; 95% CrI 0.60– 0.86). Another network meta-analysis showed that current LAMAs have similar efficacy for change in FEV₁, SGRQ, dyspnoea and rescue medication use (Ismaila 2015) [evidence level I]. However, with few head to head comparisons of LAMAs available, the choice of LAMA and inhaler device depends on patient and clinician preferences.

A meta-analysis of 9 studies of LAMA versus LABA inhalers (17, 120 COPD patients, with tiotropium as the most common LAMA) showed that LAMAs had reduced exacerbation rates (RR 0.88, 95% CI 0.84 to 0.93) and exacerbation-related hospitalisations (RR 0.78, 95% CI 0.69 to 0.87), compared to LABAs (Maia 2017) [evidence level I].

< Prev Next >